DNA Damage Response Therapy, Italian Applicants, Apr 15 2026

The European Patent Office published EP3642337A1, a patent application for therapy and diagnosis of diseases characterised by alterations in the DNA damage response, filed by Italian cancer research institutes IFOM and Istituto Europeo di Oncologia. The application covers six named inventors and is classified under multiple IPC codes including C12N 9/16 (enzymes) and A61K 31/155 (pharmaceutical preparations). The designated states include all EPO member states and extension countries.

For researchers, biotech firms, and pharmaceutical companies working in DNA damage response therapeutics or diagnostics, this publication establishes IP rights for the named applicants across a broad geographic scope. Competitors developing related oncology therapies should conduct freedom-to-operate analyses and review the full patent claims upon EPO grant.